The American Psychiatric Association (APA) has updated its Privacy Policy and Terms of Use, including with new information specifically addressed to individuals in the European Economic Area. As described in the Privacy Policy and Terms of Use, this website utilizes cookies, including for the purpose of offering an optimal online experience and services tailored to your preferences.

Please read the entire Privacy Policy and Terms of Use. By closing this message, browsing this website, continuing the navigation, or otherwise continuing to use the APA's websites, you confirm that you understand and accept the terms of the Privacy Policy and Terms of Use, including the utilization of cookies.

×
Published Online:https://doi.org/10.1176/appi.ps.57.1.123

OBJECTIVE: This study investigated whether race was associated with patterns of psychotropic medication use among veterans with bipolar disorder. METHODS: Data were examined for veterans from the mid-Atlantic region with a diagnosis of bipolar disorder in fiscal year 2001. Prescription data determined whether differences existed between black and nonblack patients in the receipt of lithium, other mood stabilizers, all mood stabilizers, first-generation antipsychotics, second-generation antipsychotics, all antipsychotics, selective serotonin reuptake inhibitors (SSRIs), tricyclic antidepressants, all antidepressants, and benzodiaze-pines. RESULTS: Data for 2,958 patients were sampled: 347 blacks and 2,611 nonblacks. Multivariable analyses that adjusted for patient and clinical factors revealed that compared with nonblacks, blacks were significantly less likely to receive lithium and SSRIs and significantly more likely to receive first-generation antipsychotics and any antipsychotic. CONCLUSIONS: These findings suggest that efforts should be made to reduce disparities in access to pharmacotherapy among patients with bipolar disorder.